Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide PK/Safety in Chinese Overweight/Obese T2DM
NCT05437848Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Cotadutide with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events at 98 days, Incidence of treatment-emergent serious adverse events at 98 days and 8 more. Started Feb 2022; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05437848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437848.